Myasthenia Gravis (Chronic Weakness) Clinical Trials

A listing of Myasthenia Gravis (Chronic Weakness) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 27 clinical trials
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG).

generalized myasthenia gravis
weakness
  • 3 views
  • 22 Sep, 2021
  • 140 locations
A Study of TAK-079 in People With Generalized Myasthenia Gravis

Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies. People with generalized myasthenia gravis have a weakness in many muscles. TAK-079 is a medicine to help people …

cholinesterase inhibitors
serologic test
mycophenolate mofetil
azathioprine
cyclosporine
  • 22 views
  • 02 Apr, 2021
  • 59 locations
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) as compared to efgartigimod IV infused in patients with generalized myasthenia gravis (gMG). The study duration is approximately 12 weeks. After screening, …

generalized myasthenia gravis
  • 0 views
  • 27 Aug, 2021
  • 42 locations
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

The purpose of this study is to evaluate the long-term safety and tolerability of efgartigimod PH20 SC 1000 mg, and the clinical efficacy, PD, pharmacokinetics (PK), immunogenicity, impact on the quality of life (QoL) of the participants, treatment satisfaction, and administration method preference, and the feasibility of self- and caregiver-supported …

generalized myasthenia gravis
acetylcholine
immune globulin
immunoglobulin g (igg)
  • 0 views
  • 04 Sep, 2021
  • 23 locations
Myasthenia Gravis Inebilizumab Trial

Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.

mycophenolate mofetil
anti-musk antibody
azathioprine
corticosteroids
immune globulin
  • 0 views
  • 02 Apr, 2021
  • 7 locations
Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study

This is a 6 month study that will evaluate the efficacy of 5mg tofacitinib tablet taken twice a day in patients with refractory myasthenia gravis. Twenty adult participants will receive a four month treatment of tofacitinib followed by elution for one month.

repetitive nerve stimulation
weakness
immune globulin
tacrolimus
acetylcholine
  • 9 views
  • 27 Aug, 2021
  • 1 location
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.

  • 0 views
  • 17 Apr, 2021
  • 1 location
Subcutaneous Immunoglobulin for Myasthenia Gravis

This is a prospective open-label, randomized, parallel arm clinical trial. The primary objective of the study is to evaluate the safety and efficacy of Cuvitru 20% subcutaneous immunoglobulin in patients with myasthenia gravis (MG). The secondary objective is to evaluate patient preferences and effects on quality of life when treating …

  • 0 views
  • 03 Feb, 2021
  • 1 location
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

generalized myasthenia gravis
immunosuppressive agents
  • 0 views
  • 17 Feb, 2021
  • 4 locations
Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis

This study examines the effect of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms.

immunomodulator
repetitive nerve stimulation
generalized myasthenia gravis
salbutamol 4mg tablet
salbutamol
  • 15 views
  • 24 Jan, 2021
  • 2 locations